Biotech and Pharma Industry News | BioPharma Dive
WEBBioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Two decades and $200 billion: AbbVie’s Humira monopoly nears …
WEBMar 17, 2022 · Its arrival will mark the end of a two-decade run of market exclusivity during which Humira’s maker, AbbVie, has earned nearly $200 billion from sales of the drug. Eight more biosimilars — as copies of biologic drugs are called — are expected to become available over the course of 2023, putting AbbVie under pressure.
Gilead wins approval of CAR-T therapy in adult leukemia
WEBOct 4, 2021 · Gilead’s cancer cell therapy Tecartus is now approved in the U.S. to treat adults with acute lymphoblastic leukemia, the treatment’s second clearance by the Food and Drug Administration and the first for a so-called CAR-T drug in people with the blood cancer who are older than 25. The approval, announced by Gilead’s Kite Pharma unit on ...
Biotech M&A has plateaued. Track the deals that are happening …
WEB3 days ago · Inside the market of emerging biotech. New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously. BioPharma Dive is tracking M&A activity below. The database, which shows drugmaker buyouts that have happened since 2018 and were valued at …
Meso Scale Discovery (MSD): An immunoassay platform with …
WEBFeb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic detection range (0.1-10 pg/mL).In addition, MSD has an efficient low volume sampling (1-25 μ L) and minimized matrix effect aiding in simultaneous multiplex detection with high precision. . Furthermore, MSD has simpler protocols, reduced ...
A three-decade monopoly: how Amgen built a patent thicket …
WEBNov 1, 2021 · A new approach to autoimmune disease. Enbrel’s origin lies in a rush of research at universities and pharmaceutical laboratories in the 1980s and 1990s to improve on immunosuppressive drugs like methotrexate and leflunomide, which were helpful, albeit flawed treatments for conditions like rheumatoid arthritis.
Biotech IPOs are the industry’s lifeblood. Track how they’re …
WEB5 days ago · IPO activity reached a peak in 2021, when more than 100 biotechs priced an initial offering and together raised nearly $15 billion. But that momentum came to a halt as 2021 turned to 2022, and stock prices of newly public companies plummeted amid a sector-wide downturn. The pace of IPOs stalled and, last year, only 19 drugmakers priced initial ...
A decade later, biotech’s CRISPR revolution is still going strong
WEBOct 11, 2023 · A cell and an injection needle are projected onto a screen during a CRISPR/Cas9 experiment in Berlin, Germany, on May 22, 2018. A research paper published a decade ago touched off a biomedical revolution that has made careers, spawned companies and drawn billions of dollars of investment. By the end of the year, the gene editing technology that ...
Biotech News - BioPharma Dive
WEBSep 13, 2024 · ArsenalBio raises $325M in one of the year’s largest biotech funding rounds. The financing comes amid a slowdown in venture investment for gene and cell therapy startups, and will support multiple solid tumor programs. …
Lilly wins FDA approval for new kind of diabetes drug
WEBMay 13, 2022 · The Food and Drug Administration on Friday approved Eli Lilly’s diabetes drug Mounjaro, a first-of-its-kind treatment that can help control patients’ blood sugar and, potentially, help them lose weight as well. Mounjaro, also known as tirzepatide, expands Lilly’s diabetes business, which includes insulins as well as other types of therapies.
Skip to content